Chronic kidney disease and erectile dysfunction frequently occur together, but the connection is often missed in routine care. Kidney disease can affect blood vessels, hormones, nerves, energy, and emotional health—all systems that contribute to an erection. The association does not mean every man with reduced kidney function will develop erectile dysfunction (ED), nor does ED establish a diagnosis of kidney disease. It does mean that persistent changes in erectile function deserve a thoughtful medical evaluation rather than being dismissed as an inevitable part of aging.
How Chronic Kidney Disease and Erectile Dysfunction Are Connected
An erection is a vascular and neurologic event. Sexual stimulation triggers nitric oxide release in penile tissue, increasing cyclic guanosine monophosphate (cGMP). The smooth muscle in penile arteries and erectile tissue relaxes, blood flow rises, and venous outflow is temporarily restricted. Disease anywhere along this pathway can reduce rigidity or make an erection harder to maintain.
Chronic kidney disease (CKD) is defined by structural kidney damage or reduced kidney function that persists for at least three months. As kidney function declines, the effects extend beyond filtration. CKD promotes endothelial dysfunction, oxidative stress, chronic inflammation, arterial stiffness, and disturbances in mineral metabolism. These changes can reduce nitric oxide bioavailability and impair the ability of small arteries to dilate.
The penile arteries are relatively small, so vascular dysfunction may become apparent there before it causes symptoms in larger vessels. Diabetes and hypertension—the two leading causes of CKD—also independently damage blood vessels and nerves. Consequently, ED in a man with CKD is usually multifactorial rather than attributable to one laboratory value or one hormone.
The overlap is common. A systematic review and meta-analysis by Pizzol and colleagues included 34 studies and 5,986 men with CKD. The pooled prevalence of ED was 76%, although estimates varied considerably among studies. Prevalence was 78% in reported CKD cohorts, 77% among men receiving hemodialysis, and 64% after kidney transplantation.[1] These figures describe populations, not an individual prognosis, but they show why sexual health should be part of kidney care.
Vascular, Hormonal, and Metabolic Mechanisms
Endothelial dysfunction is a central link. Healthy endothelium releases nitric oxide in response to stimulation. In CKD, uremic toxins, inflammation, and oxidative stress can reduce nitric oxide production and accelerate its breakdown. The result may be an inadequate arterial response even when sexual desire and nerve signaling remain intact.
Hormonal changes can add another layer. Men with advanced CKD may have reduced testosterone, elevated prolactin, and disruption of the hypothalamic-pituitary-gonadal axis. Low testosterone is more closely related to reduced desire and overall sexual well-being than to every case of ED, but it may worsen erectile symptoms or blunt response to treatment. Testosterone should be measured under appropriate morning conditions and interpreted with symptoms; treatment should not be based on a single borderline result.
Anemia can contribute through fatigue, reduced exercise tolerance, and diminished quality of life. Abnormal calcium-phosphate balance, secondary hyperparathyroidism, autonomic dysfunction, and peripheral neuropathy may also play roles. A 2024 epidemiological study of 98 Brazilian men undergoing hemodialysis found ED in 66.3%. Older age, diabetes, lower mean corpuscular hemoglobin, higher calcium, and lower albumin were among the associated factors.[2] Because the study was cross-sectional, it cannot show that any one factor caused ED, but its findings illustrate the interacting clinical burden.
Medication effects should be reviewed rather than assumed. Some antihypertensives, antidepressants, sedatives, and hormonal agents may affect sexual function, yet abruptly stopping them can be dangerous. In many cases, uncontrolled blood pressure, depression, or vascular disease poses a greater risk to erectile function than the medication used to treat it. A clinician can evaluate timing, alternatives, and dose while protecting kidney and cardiovascular health.
Why Kidney Disease Stage and Dialysis Matter
ED may occur at any CKD stage, but symptom burden often increases with more advanced disease and accumulating comorbidities. A 2024 cross-sectional study in Scientific Reports evaluated 72 men across CKD settings and found ED in 56.9%. The study also identified substantial rates of reduced desire, ejaculatory concerns, and dissatisfaction, reinforcing that sexual dysfunction is broader than erection quality alone.[3]
Dialysis does not automatically cause ED, and starting dialysis does not guarantee that erectile function will worsen. However, men receiving dialysis often have advanced vascular disease, anemia, medication burden, fatigue, altered hormones, and demanding treatment schedules. Fluid shifts and blood-pressure changes around a dialysis session may also influence how a man feels. Timing sexual activity when energy and blood pressure are more stable may help some men, although this is an individualized practical strategy rather than a treatment for the underlying problem.
Kidney transplantation may improve endocrine balance, anemia, physical health, and sexual function, but improvement is not universal. Pre-existing arterial disease, diabetes, medication effects, graft function, and psychological factors can persist. The lower pooled ED prevalence after transplantation in the Pizzol meta-analysis is encouraging but should not be interpreted as proof that transplantation itself resolves ED in every patient.[1]
Importantly, ED can affect self-esteem, intimacy, mood, and treatment adherence. Men may not volunteer the symptom, and clinicians may not ask. Normalizing a brief sexual-health discussion can uncover treatable contributors without implying that sex is the most important outcome of kidney care.
Evaluation: What a Clinician May Check
Evaluation begins with the pattern of symptoms. Clinicians generally ask whether the problem involves obtaining an erection, maintaining it, reduced rigidity, reduced desire, orgasm, or ejaculation. Sudden onset, preserved spontaneous or morning erections, and strong situational variation may suggest a substantial psychogenic component, while gradual progression with fewer spontaneous erections may be more consistent with organic disease. Many men have both.
A medication and substance review is essential. Alcohol, nicotine, cannabis, opioids, and nonprescribed supplements can influence sexual function or interact with treatment. The physical examination may assess blood pressure, pulses, body composition, genital findings, and signs of hormonal or vascular disease.
Laboratory testing should be targeted. Depending on the clinical context, it may include kidney function and electrolytes, blood count, glucose or hemoglobin A1c, lipid profile, and morning total testosterone. Additional endocrine testing may be appropriate when symptoms or the initial results support it. Cardiovascular fitness for sexual activity also matters, particularly in men with chest pain, unstable heart disease, severe shortness of breath, or poorly controlled blood pressure.
Persistent ED should not be treated as a purely cosmetic complaint. It can be a marker of systemic endothelial disease. A proper evaluation may identify diabetes, uncontrolled hypertension, depression, medication effects, or hormonal abnormalities that deserve attention in their own right. More evidence-based discussions of related risk factors are available in the men's health library.
Treatment Options and Kidney-Specific Safety
Management starts with modifiable contributors where feasible. Smoking cessation, regular aerobic and resistance exercise, adequate sleep, weight management, and control of diabetes and blood pressure may support vascular health. These measures do not guarantee reversal of ED, especially in advanced CKD, but they address shared mechanisms and may improve treatment response. Counseling or sex therapy can be useful when performance anxiety, depression, relationship strain, or adjustment to chronic illness is present.
Phosphodiesterase type 5 (PDE5) inhibitors enhance the cGMP pathway; they support the erectile response to sexual stimulation rather than creating an automatic erection. A review of controlled and observational studies in men receiving dialysis or living with a kidney transplant found that sildenafil improved erectile-function measures, with 75% to 85% reporting improvement on global assessment questions in double-blind, placebo-controlled studies. Vardenafil also improved scores in small controlled transplant studies, while data for tadalafil were more limited at the time.[4]
Kidney function affects medication selection and dosing. Some PDE5 inhibitors or their metabolites remain in the body longer when renal clearance is reduced. Product labeling places specific limits on tadalafil in severe renal impairment and does not recommend once-daily tadalafil when creatinine clearance is below 30 mL/min or in men receiving hemodialysis. Individual factors—including dialysis status, blood pressure, other medications, and liver function—must therefore be reviewed by a prescriber.
PDE5 inhibitors must not be combined with nitrates such as nitroglycerin because the combination can cause a dangerous fall in blood pressure. Caution is also needed with alpha-blockers and in men with unstable cardiovascular disease. Common adverse effects include headache, flushing, nasal congestion, indigestion, and back or muscle discomfort, depending on the agent. Sudden vision or hearing changes and an erection lasting more than four hours require urgent medical attention.
When oral therapy is unsuitable or ineffective, options may include vacuum erection devices, intraurethral or intracavernosal medication, and penile prosthesis surgery. The appropriate sequence depends on goals, dexterity, bleeding risk, infection risk, cardiovascular status, and kidney-disease severity. A recent review covering studies published from 2020 through 2024 concluded that treatment can be effective in CKD, but careful assessment and more high-quality trials remain necessary.[5]
Conclusion
Chronic kidney disease can affect erections through vascular injury, reduced nitric oxide signaling, hormonal disruption, anemia, neuropathy, medication effects, and psychological stress. ED is common in CKD, including among men receiving dialysis, but it is neither universal nor untreatable. The most useful approach is comprehensive: define the symptom, assess cardiovascular and metabolic risk, review medications, identify reversible contributors, and select treatment that fits the degree of renal impairment.
If you're exploring clinically formulated options, OnyxMD's EPIQ CHEWS are available through physician-supervised treatment plans when medically appropriate, starting with a free online assessment at questionnaire.getonyxmd.com. A prescriber must review kidney function and other medications before determining whether this or any PDE5-based option is suitable.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Pizzol D, Xiao T, Yang L, et al. Prevalence of erectile dysfunction in patients with chronic kidney disease: a systematic review and meta-analysis. International Journal of Impotence Research. 2021;33(5):508-515. doi:10.1038/s41443-020-0295-8
Barros Neto J, Teixeira TA, Silva FT, Rocha KD, Almeida HKS, Nazima MTST. Erectile dysfunction among men with chronic kidney disease undergoing hemodialysis in a Brazilian Amazon urban setting: an epidemiological study. Jornal Brasileiro de Nefrologia. 2024;46(4):e20240065. doi:10.1590/2175-8239-JBN-2024-0065en
Fu R, He P, Hong W, Liang Y, Wang W, Yuan S, Liu L. Male sexual dysfunction in patients with chronic kidney disease: a cross-sectional study. Scientific Reports. 2024;14:9207. doi:10.1038/s41598-024-59844-4
Vecchio M, Navaneethan SD, Johnson DW, et al. Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation. The Journal of Sexual Medicine. 2013;10(11):2798-2814. doi:10.1111/jsm.12038
Papadopoulou E, et al. Erectile dysfunction in chronic kidney disease and hemodialysis patients: a state-of-the-art review. Cureus. 2025;17(2):e79292. doi:10.7759/cureus.79292
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.